BaDGE ® vector-free DNA / RNA therapeutic
BaDGE ® Vector-free DNA / RNA Therapeutics
On-target naked gene-based therapies in an instant
Learn More
Challenge
• vector-based delivery of DNA / RNA therapeutics by virus and lipid nanoparticles is challenged by packaging limits, stability, and‘ leaky’ biodistribution( lack of precision gene expression targeting within tissues).
• immune priming precludes further treatments.
Solution
BaDGE ® achieves precise spatiotemporal control of the dose of naked nucleic acid molecules( stable and bioinert outside of targeted cells), enabling precision gene-based medicine with repeated dosing and treatment options. The safety and efficacy of the process was validated in a first-in-human clinical trial for nerve repair.
Target customers / end-users
• delivery solutions
• pharma seeking solutions to neovascular diseases( VEGF-inhibition), nerve injury( BNDF & NT3 neurotrophins), and brain excitability( K + channels)
Progress
• R & D(> AUD10 million); Australia Economic Accelerator Ignite funding for commercialisation of‘ Vision- BaDGE’ wetAMD therapy
• biotech partnerships for BaDGE device and GMP DNA manufacture
• validated in first-in-human clinical trial
Spinout
Validated( real-world setting)
TRL 7
Multidisciplinary team
Healthy Living
BaDGE ® has experience in medical-device development and therapeutics with academicbiotech crossover. It offers proprietary technology, patent coverage, scientific journal commentary, and validated clinical leads.
74 •